MedPath

Comparison of Methacholine Bronchial Provocation With Wright and Devilbiss646 Nebulizers

Not Applicable
Completed
Conditions
Asthma
Registration Number
NCT02502825
Lead Sponsor
Guangzhou Institute of Respiratory Disease
Brief Summary

The purpose of this study is to compare the diagnostic validity (sensitivity and specificity) and evaluate the safety of 2-min Tidal Breathing methacholine bronchial provocation tests with the Wright and Devilbiss646 nebulizers in asthmatic in Guangzhou.

Detailed Description

After screening,each asthmatic patient will visit the investigators' center 4 times.

During the first week, the patient will be randomised to undergo methacholine bronchial challenge with Wright or Devilbiss 646 nebulizer on two separate days, which are at least 24 hours but not more than 7 days apart.The above procedure will be repeated for each patient in one month. But the nebulizer will be selected in a reverse order.Provocative concentration induced a 20% decrease in forced expiratory volume in one second (PC20) will be calculated for each test. Record all the adverse events during the tests.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
22
Inclusion Criteria
  • clinical diagnosis of asthma;
  • stable for more than 4 weeks with FEV1≥65%pred
Exclusion Criteria
  • exacerbation within 3 months;
  • upper airway infections within 4 weeks;
  • concomitant of hypertension or heart diseases;
  • pregnancy;
  • under immunotherapy

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
percentage of the participants that tested positive to methacholine bronchial provocation with Wright or Devilbiss646 nebulizer5 minutes after each challenge
Secondary Outcome Measures
NameTimeMethod
Incidence and severity of Adverse Events during the methacholine bronchial provocation tests with Wright nebulizer and Devilbiss646 nebulizerduring and until 5 minutes after each challenge

Trial Locations

Locations (1)

Guangzhou institute of respiratory disease

🇨🇳

Guangzhou, Guangdong, China

Guangzhou institute of respiratory disease
🇨🇳Guangzhou, Guangdong, China

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.